Canada \u00b7 Zepbound
Zepbound in Canada: approval and real user reports.
Zepbound is the weight-management brand of tirzepatide, a dual GIP and GLP-1 receptor agonist. Health Canada authorized it on May 13, 2025 and Eli Lilly Canada announced availability on July 9, 2025. Here is what that means, and what anonymous tirzepatide users report.
Zepbound vs Mounjaro vs “research” tirzepatide
- Zepbound — prescription tirzepatide for chronic weight management.
- Mounjaro — prescription tirzepatide for type 2 diabetes (Mounjaro in Canada).
- “Research” tirzepatide — not authorized (why).
Look up any product's DIN in the Drug Product Database.
What tirzepatide users report
- 93 published anonymous tirzepatide confessions; 27 mention at least one side effect.
- 10 mention Mounjaro or Zepbound by name.
- Among confessions that state a weight change in pounds, the median reported is 50 lb. Self-reported, unverified.
Most-mentioned side effects (share of tirzepatide confessions):
- Heart rate or palpitations: 11.8% (11)
- Anxiety or panic: 5.4% (5)
- Burping: 4.3% (4)
- Insomnia or poor sleep: 3.2% (3)
- Libido: 3.2% (3)
Counts are phrase mentions in anonymous accounts, not diagnoses or clinical rates. Full breakdown and methodology: tirzepatide side-effects report.
By province and city
What the SURMOUNT-1 trial showed
Averages from the 72-week trial in adults with obesity or overweight without diabetes (NEJM, 2022). Not a prediction for any one person.
| Outcome | Tirzepatide (all doses) | Placebo |
|---|---|---|
| Average weight change | About 15% to 21% lower, depending on dose | About 3% lower |
| Nausea | About 25% to 33% | About 10% |
| Diarrhea | About 19% to 23% | About 7% |
| Constipation | About 12% to 17% | About 6% |
| Vomiting | About 8% to 12% | About 2% |
Last reviewed October 15, 2026against Health Canada's Drug Product Database and SURMOUNT-1 and Health Canada sources.
Coverage and what to ask
Public drug plans generally do not pay for weight-management drugs; some private plans do. See Is Zepbound covered in Canada? and Mounjaro coverage. Ask a prescriber about gallbladder disease, pancreatitis history, pregnancy plans and other medicines, and note that tirzepatide can make oral birth control less reliable for a time after starting or increasing it.
Related
Frequently asked questions
- How much weight do people lose on Zepbound?
- In the SURMOUNT-1 trial, average weight loss over 72 weeks was about 15% to 21% depending on dose, versus about 3% on placebo. Individual results vary widely.
- Is Zepbound covered in Canada?
- Public plans generally don't cover weight-management drugs. Some private plans do; check your plan.
- Is Zepbound approved in Canada?
- Yes. Health Canada authorized Zepbound (tirzepatide) on May 13, 2025 for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. Eli Lilly Canada announced availability on July 9, 2025.
- Is Zepbound the same as Mounjaro?
- Both are Eli Lilly's tirzepatide. In Canada Mounjaro is authorized for type 2 diabetes and Zepbound for chronic weight management.
- Is Zepbound prescription-only in Canada?
- Yes. Zepbound is listed as a prescription drug in Health Canada's Drug Product Database.
- Does this page say where to get Zepbound or how much to take?
- No. We do not publish sourcing, pricing or dosing. Talk to a licensed Canadian prescriber or pharmacist.
Sources
General information only — not medical, legal or regulatory advice. Peptide Confessions does not sell, source or recommend any product or vendor, and nothing here is dosing guidance. Speak with a licensed Canadian healthcare professional or pharmacist about any medication. Editorial process →